IMARC Group’s latest report, titled “Radiodermatitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” finds that the global radiodermatitis market size reached US$ 481.9 Million in 2022. Radiodermatitis, also known as radiation dermatitis, is a skin condition that usually occurs as a side effect during cancer treatment or after interventional radiology. It is caused by radiation therapy used for the treatment of patients with cancers of the breast, lungs, skin, neck, head, or perineum region, wherein the skin is part of the target field. It can be treated using various products, such as hydrophilic creams, hydrogel and hydrocolloid dressings, silicone-coated dressings, silver-leaf dressings, oral analgesics, anti-inflammatory agents, topical antibiotics, and corticosteroids. Since it helps minimize discomfort, reduce pain, and prevent interruption in ongoing therapy while enhancing the overall quality of the patient’s life, radiodermatitis treatment has gained immense traction across the globe.
Global Radiodermatitis Market Trends:
The rising incidences of different cancers among the masses owing to unhealthy lifestyles and excessive smoking and alcohol consumption have led to the widespread adoption of radiation therapy as a treatment option. This, coupled with the surging need to manage the adverse side effects of radiation therapy, represents the primary factor driving the market growth. Apart from this, the increasing public and private funding in ongoing research and development (R&D) activities in the field of life sciences are positively influencing the market growth. In addition, numerous governmental and non-governmental organizations are taking favorable initiatives to spread awareness about the available radiodermatitis treatment and management solutions. Along with this, the escalating demand for novel wound care products and the increasing number of clinical trials are contributing to the market growth. Furthermore, several key players are launching innovative product variants to expand their product portfolio and customer base. In line with this, elevating sales of generic drugs via online and offline distribution channels has catalyzed market growth. Other factors, including the expanding geriatric population, improvements in the healthcare infrastructure, easy availability of supportive healthcare reimbursement policies, and rising consumer healthcare spending, are also providing a positive thrust to the market growth. Looking forward, IMARC Group expects the market value to reach US$ 597.9 Million by 2028, growing at a CAGR of 3.5% during 2023-2028.
- Based on the product, the market has been segregated into topical (corticosteroids, hydrophilic creams, antibiotics, and others), oral, and dressings (hydrogel and hydrocolloid dressings, no sting barrier film, honey-impregnated gauze, silicone-coated dressings, and others).
- On the basis of the distribution channel, the market has been classified into hospital, retail, and online pharmacies.
- Region-wise, the market has been divided into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
- The competitive landscape of the market has also been examined, with some of the key players being 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Mölnlycke Health Care AB, and Stratpharma AG.
|Base Year of the Analysis
||Product, Distribution Channel, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Mölnlycke Health Care AB and Stratpharma AG
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N A
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800